Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Arcus reported financial results for the nine months ended September 30, 2026.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Arcus reported financial results for the nine months ended September 30, 2026
- Exhibit 99.1 contains the detailed results and management commentary
- Results announcement dated November 4, 2026
Item EX-99.1 · Exhibit EX-99.1
- Casdatifan clinical momentum: PEAK-1 enrollment expected complete within two to three months, with PEAK-20 Phase 3 initiation targeted for Q4 2026
- ARC-20 results showed median PFS 14.5 months in second-line disease and median OS 35 months in heavily pretreated patients
- 2027 catalysts: mature PFS and OS data across first- and second-line cohorts, plus late-line combination efficacy and safety data
- Cash $694M plus $288M October equity proceeds, supporting planned operations into 2029 but increasing dilution risk
- Q3 revenue $9M versus $26M, net loss $128M versus $135M, with full-year 2026 revenue guidance of $70M to $75M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.